As the world charges to vaccinate the population against the coronavirus, gene therapy developers are locked in a counterintuitive race. Instead of training the immune system to recognize and combat a virus, they’re trying to do the opposite: designing viruses the body has never seen, and can’t fight back against.
It’s OK, really: These are adeno-associated viruses, which are common and rarely cause symptoms. That makes them the perfect vehicle for gene therapies, which aim to treat hereditary conditions caused by a single faulty gene. But they introduce a unique challenge: Because these viruses already circulate widely, patients’ immune systems may recognize the engineered vectors and clobber them into submission before they can do their job.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Log In | Learn More
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Daily reporting and analysis
The most comprehensive industry coverage from a powerhouse team of reporters
Daily newsletters to brief you on the most important industry news of the day
Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
Exclusive industry events
Premium access to subscriber-only networking events around the country
The best reporters in the industry
The most trusted and well-connected newsroom in the health care industry
And much more
Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.